News &amp; Updates

Simplified risk-stratified aspirin protocol safe, effective in patients undergoing joint arthroplasty

A simplified risk stratification protocol used to select patients for twice-daily aspirin therapy for venous thromboembolism (VTE) prophylaxis has been shown to be safe and effective in those undergoing total joint replacement (TJR), reports a recent study.

Simplified risk-stratified aspirin protocol safe, effective in patients undergoing joint arthroplasty

Rare cases of IBD onset seen in patients with psoriasis on IL-17 inhibitors

The risk of new-onset inflammatory bowel disease (IBD) among patients with psoriasis exposed to interleukin-17 inhibitor (IL-17i) appears to be comparable to that among unexposed individuals, suggests a study. In addition, the incidence of IBD in exposed patients is low.

Rare cases of IBD onset seen in patients with psoriasis on IL-17 inhibitors

Dolutegravir suppresses HIV in pregnant women without upping neural tube defect risk

10 Aug 2020 by

The benefit of using dolutegravir for HIV treatment in pregnant women outweighs the risk. This is the message delivered by two studies presented at the 23rd International AIDS Conference, which have shown that the drug induces rapid viral suppression and brings a slight but nonsignificant risk of neural tube defects (NTDs) compared with other antiretrovirals.

Dolutegravir suppresses HIV in pregnant women without upping neural tube defect risk

Phenobarbital safe, effective for alcohol withdrawal syndrome in psychiatric inpatients

09 Aug 2020

Use of phenobarbital is effective for the prevention and treatment of alcohol withdrawal syndrome (AWS) in psychiatric inpatients, a study has shown. Moreover, it is safe and neither leads to severe adverse effects nor requires a higher level of care.

Phenobarbital safe, effective for alcohol withdrawal syndrome in psychiatric inpatients

09 Aug 2020

$Delayed denosumab injections up fracture risk in osteoporotic patients$

Delayed denosumab injections up fracture risk in osteoporotic patients

Delayed administration of subsequent denosumab doses by >16 weeks may lead to additional vertebral fracture risk compared with on-time dosing, results of a population-based cohort study have shown. However, there is not enough evidence to conclude that fracture risk is elevated at other anatomical sites with long delay.

Delayed denosumab injections up fracture risk in osteoporotic patients

Denosumab exerts delaying effects on skeletal-related events in at-risk cancer patients

Denosumab bests zoledronic acid at preventing skeletal-related events in vulnerable cancer patients, according to the results of a meta-analysis. The former also shows a better tolerability profile despite being associated with potential yet manageable adverse events.

Denosumab exerts delaying effects on skeletal-related events in at-risk cancer patients

VERTIS CV highlights CV safety of ertugliflozin in T2D

07 Aug 2020 by

Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.

VERTIS CV highlights CV safety of ertugliflozin in T2D

Thrombotic complications in COVID-19 inpatients: updates from ISTH

07 Aug 2020 by

Thrombotic complications are rife among in-hospital patients with COVID-19, with patients in the ICU particularly at risk compared with those in the general wards, a study released at the ISTH 2020 Meeting has shown.

Thrombotic complications in COVID-19 inpatients: updates from ISTH

Canakinumab exerts lasting effects in colchicine-resistant familial Mediterranean fever

Patients with colchicine-resistant familial Mediterranean fever benefit from long-term treatment with canakinumab, preventing flares and controlling disease activity without increasing adverse events, according to the results of a phase III study.

Canakinumab exerts lasting effects in colchicine-resistant familial Mediterranean fever